Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder
Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder
Not yet recruiting · NCT07838311 · Registry updated 2026-09-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder | Chemically-Induced Disorders, attention deficit hyperactivity disorder, inattentive type, cannabis dependence, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder, substance-related disorder | Not yet recruiting | Phase 4 | 2026-09-28 | NCT07838311 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Collegium Pharmaceutical, Inc. | 1 |
| Massachusetts General Hospital | 758 |
| National Institute on Drug Abuse (NIDA) | 549 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Massachusetts General Hospital, 55 Fruit Street, Yawkey 6A | Boston | United States | 1 |